Pregnant	Comments
No	

Sex and Gender Information	Value	Date Recorded
Sex Assigned at Birth	Female	07/14/2026 5:39 PM PDT
Legal Sex	Female	09/27/2018 1:19 PM PDT
Gender Identity	Female	07/14/2026 5:39 PM PDT
Sexual Orientation	Straight	07/14/2026 5:39 PM PDT

Travel History	Travel Start	Travel End
California	11/09/2026	11/13/2026

documented as of this encounter

Last Filed Vital Signs

Not on file

documented in this encounter

Progress Notes

Kate Bialick - 10/08/2026 10:30 AM PDT

Formatting of this note might be different from the original.
Update 10/23: Breast onc asked OCC to move up follow up from 11/5 to 10/30 to check ANC. If ANC recovers on 10/30, can keep 600mg dose. If still low, team may want DR. Changed lab orders to 10/30 to be coordinated with UW Montlake appt. Beejal R Ganti, PharmD

Oral Chemotherapy Monitoring Program

Oral chemotherapy management per FHCC CDTA

Yvonne Kalley Franklin is a 47 year old female contacted for follow up by phone for oral chemotherapy treatment monitoring.

Indication: ER/PR+, HER2- Metastatic Breast Cancer
Treatment Plan/Dose: Ribociclib 600mg PO daily D1-21/28 + Anastrozole + Leuprolide
Cycle: Subsequent Review-Refill Rx

Cycle Start Date: 09/12/26
Anticipated Next Cycle Start Date: 10/10/26

Treatment delayed or held?: Yes
Reason: XRT to sacrum planned 10/1-10/7, held ribociclib 9/30-10/2

Problem list

Patient Active Problem List

Diagnosis

- Secondary malignant neoplasm of bone (HCC)
- Neck pain

- Cancer related pain
- Breast cancer metastasized to bone, unspecified laterality (HCC)
- Acute bilateral thoracic back pain
- Pathologic compression fracture of vertebra (HCC)
- Metastatic malignant neoplasm (HCC)
- Cancer, metastatic to bone (HCC)

Allergies Review of patient's allergies indicates:

Allergies

Allergen Reactions

- Fentanyl Other

Isolated PVCs
8/20/2026 states took Fentanyl without incident.
9/16/2026 took fentanyl without incident

- Propofol Palpitations and Other

PVC's

Palpitation

9/16/2026 took propofol without incident

Recent Labs:

CMP

Recent Labs

Units 10/07/26
1300 09/25/26
0810

Sodium meq/L 136 139

Potassium meq/L 4.2 3.8

Chloride meq/L 103 101

Carbon Dioxide, Total meq/L 32 29

Anion Gap 1 L 9

Glucose mg/dL 106 103

Urea Nitrogen mg/dL 11 13

Creatinine mg/dL 0.54 0.63

Calcium mg/dL 8.2 L 8.9

Total Protein (Beckman) g/dL 6.1 --

Total Protein (Roche) g/dL -- 6.6

Albumin g/dL 4.1 4.4

Total Bilirubin (Beckman) mg/dL 0.7 --

Total Bilirubin (Roche) mg/dL -- 0.7

AST (Beckman) U/L 16 --

AST (Roche) U/L -- 20

Alkaline Phosphatase (Total) U/L 83 133 H

ALT (Beckman) U/L 11 --

ALT (Roche) U/L -- 13

CBC, DIFF

Recent Labs

Units 10/07/26
1300 09/25/26
0810

WBC 10*3/uL 2.04 L 3.18 L

Hemoglobin g/dL 10.7 L 11.7

Hematocrit % 33 L 36

Platelet Count 10*3/uL 183 290

Neutrophils 10*3/uL 0.91 L 1.46 L

Medications

Current Outpatient Medications

Medication Instructions

- acetaminophen (TYLENOL) 975 mg, Every 8 hours scheduled
- albuterol HFA 108 (90 Base) MCG/ACT inhaler 2 puffs, Every 4 hours PRN
- anastrozole (ARIMIDEX) 1 mg, Oral, Daily
- cholecalciferol (VITAMIN D-3) 4,000 units, Daily
- lidocaine viscous 2 % mouth/throat solution 5 mL, Oral, 4 times daily PRN
- morphine ER (MS CONTIN) 30 mg, Oral, Every 8 hours scheduled, Take with a 15 mg tablet for a total of 45 mg every 8 hours
- morphine ER (MS CONTIN) 15 mg, Oral, Every 8 hours scheduled, Take with a 30 mg tablet for a total of 45 mg every 8 hours
- naloxone 4 MG/0.1ML nasal spray Use 1 spray in one nostril for suspected opioid overdose. Call 911. If unresponsive in 2 to 3 minutes, repeat with new naloxone nasal spray in opposite nostril.
- ondansetron (ZOFRAN) 8 mg, Every 8 hours
- oxyCODONE 10 mg, Oral, Every 3 hours PRN
- pantoprazole (PROTONIX) 40 mg, Oral, Daily empty stomach
- polyethylene glycol 3350 (MIRALAX) 17 g, Daily
- propranolol (INDERAL) 10 mg, Daily
- ribociclib (600 mg dose) (KISQALI) 600 mg, Oral, Daily, Take on days 1 to 21 followed by 7 days off. Repeat every 28 days.

- senna (SENOKOT) 17.2 mg, Oral, Nightly PRN
- tretinoin 0.025 % cream 1 application, 3 times weekly

Medication History
Pt reports changes to their medication on med list: No

Possible drug interactions:
Rx Interactions
Clinically relevant drug interactions identified?: No

Adherence Assessment:
Rx-Adherence
Was adherence assessed during this encounter?: Yes
Patient reported X missed doses in the last month: 0
Patient reported taking incorrect dose in the last month: No
Refill history reviewed?: Yes
Concerns for Adherence?: No

Symptom/Toxicities Assessment:
Patient reports the following side effects:
Side effects to report?: Yes

Gastrointestinal: Nausea: Grade 1 (residual nausea from radiation, using ondansetron and compazine);

Interventions and Follow-up Plan:
Plan: Reviewed 10/7 labs with ANC 0.91, lower than previous ANC's during week off likely due to radiation. Yvonne feels much improved from radiation with some lingering nausea and lower appetite from yesterday's radiation treatment. We discussed starting her cycle as planned on 10/10. Next follow-up on 11/6 with local labs on 11/5 at Evergreen Hospital.

Follow-up Dates:
Date of next outreach:: 11/05/26
Next Outreach type:: Phone
Date of next pharmacist lab review:: 11/05/26
Next refill due: 11/05/26
Reference: MONALEESA-2

Kate Bialick, PharmD

Electronically signed by Kate Bialick at 10/08/2026 11:16 AM PDT
Electronically signed by Beejal R Ganti at 10/23/2026 1:33 PM PDT

documented in this encounter